Weight loss medications: Nursing pharmacology
Definitions & Key takeaways
Weight loss medications can help manage obesity in the short term, and include anorexiants, sympathomimetic medications, lipase inhibitors, GLP-1 receptor agonists, and opioid antagonists with atypical antidepressants. However, clients can experience different side effects depending on the medication taken, such as agitation, anxiety, oily rectal leakage, headaches, dizziness, and abdominal pain. Weight loss medications are contraindicated in individuals with a history of stroke, seizures, and psychiatric conditions like anorexia nervosa, depression, and bipolar disorder.
When caring for a client prescribed weight loss medication, a nursing assessment should be done to establish a baseline for weight, BMI, and vital signs. Client education is a crucial aspect of care, with a focus on safe self-administration of the medication, recognizing and reporting side effects, and adhering to any lifestyle modifications recommended by the healthcare provider, such as changes in diet and exercise.
Introduction0:00–0:20
Anorexiants0:20–0:47
Sympathomimetic medications0:47–1:16
Lipase inhibitors1:16–1:31
GLP-1 receptor agonists1:31–1:56
Opioid antagonists and atypical antidepressants1:56–2:33
Side effects2:33–5:18
Contraindications and cautions5:18–6:14
Nursing considerations & client education6:14–8:32
Review8:32–9:59
| WEIGHT LOSS MEDICATIONS | |||
| DRUG NAME | benzphetamine hydrochloride (Didrex), diethylpropion hydrochloride (Tenuate) | orlistat (Xenica, Alli) | phentermine (Ionamin) |
| CLASS | Anorexiants | Lipase inhibitors | Sympathomimetic medications |
| MECHANISM OF ACTION | ↑ release of norepinephrine and dopamine in the satiety center → ↓ appetite | Inhibit fat absorption in the GI tract | ↓ reuptake of norepinephrine and dopamine → ↑ concentration of norepinephrine and dopamine in the synaptic cleft → ↓ perception of hunger |
| ROUTE(S) OF ADMINISTRATION |
| ||
| SIDE EFFECTS |
|
|
|
| WEIGHT LOSS MEDICATIONS, PART 2/3 | ||
| DRUG NAME | liraglutide (Saxenda, Victoza) | naltrexone/bupropion (Contrave) |
| CLASS | GLP-1 receptor agonists | Opioid antagonists & Atypical antidepressants |
| MECHANISM OF ACTION |
| Bupropion: Stimulates POMC neurons in the hypothalamus to ↑ release of hormones → ↑ energy output & ↓ appetite Naltrexone: Binds to opioid receptors without activating them, → POMC neurons stay stimulated longer by bupropion |
| ROUTE(S) OF ADMINISTRATION | SubQ | PO |
| SIDE EFFECTS |
|
|
| WEIGHT LOSS MEDICATIONS, PART 3/3 | |||
| DRUG NAME | (all drugs from parts 1&2) benzphetamine hydrochloride (Didrex), diethylpropion hydrochloride (Tenuate, orlistat (Xenica, Alli), phentermine (Ionamin), liraglutide (Saxenda, Victoza), naltrexone/bupropion (Contrave) | ||
| INDICATIONS |
| ||
| CONTRA- INDICATIONS AND CAUTIONS |
| ||
| NURSING CONSIDERATIONS | Assessment and Monitoring Assessment
Monitoring
Client Education
| ||
- "Focus on Nursing Pharmacology" LWW (2019)
- "Pharmacology" Elsevier Health Sciences (2014)
- "Mosby's 2021 Nursing Drug Reference" Mosby (2020)
- "Saunders Comprehensive Review for the NCLEX-RN Examination" Saunders (2016)
- "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)
- "Addiction potential of phentermine prescribed during long-term treatment of obesity" International Journal of Obesity (2013)
- "Lehne's Pharmacology for Nursing Care" Elsevier Health Sciences (2014)
- "Orlistat" StatPearls Publishing LLC (2021)
- "Obesity" Merck Manual (2021)
- "Orlistat" Medline Plus (2016)
No notes for this video yet
Try adding a note below